{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:51Z","timestamp":1792712451728,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2026JJ50154"],"award-info":[{"award-number":["2026JJ50154"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Melanoma is a highly aggressive malignancy in which dysregulated ubiquitin-dependent signaling contributes to tumor progression.\n                    <jats:italic>OTUD4<\/jats:italic>\n                    is frequently downregulated in melanoma, but the functional significance of this alteration remains unclear. Here, we identify OTUD4 as a dual-mode deubiquitinase that suppresses melanoma progression by coordinating K48- and K63-linked polyubiquitination. OTUD4 directly binds and stabilizes CYLD by counteracting K48-linked polyubiquitination, whereas it independently binds BCL3 and counteracts BCL3 K63-linked polyubiquitination. OTUD4 depletion promotes BCL3 ubiquitination and nuclear translocation in melanoma cells, leading to increased melanoma cell proliferation and tumor growth in clonogenic and xenograft assays. Clinically, expression of\n                    <jats:italic>OTUD4<\/jats:italic>\n                    and\n                    <jats:italic>CYLD<\/jats:italic>\n                    progressively decreases from normal skin through benign nevi to melanoma, with a further reduction in highly metastatic tumors. Reduced expression of\n                    <jats:italic>OTUD4<\/jats:italic>\n                    and\n                    <jats:italic>CYLD<\/jats:italic>\n                    is associated with poor prognosis in patients with melanoma. Together, these results reveal an OTUD4\u2013CYLD\u2013BCL3 regulatory axis in melanoma, in which OTUD4 stabilizes CYLD and inhibits BCL3 activity.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09130-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:45:35Z","timestamp":1785213935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OTUD4 stabilizes CYLD and counteracts BCL3 K63-linked polyubiquitination to suppress melanoma progression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2003-5186","authenticated-orcid":false,"given":"Yuming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3618-310X","authenticated-orcid":false,"given":"Zhaohui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0937-2815","authenticated-orcid":false,"given":"Zhiming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9856-3917","authenticated-orcid":false,"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"9130_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2023;14:1516.","journal-title":"Nat Commun"},{"key":"9130_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"9130_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.","journal-title":"Signal Transduct Target Ther"},{"key":"9130_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","volume":"1871","author":"I Kozar","year":"2019","unstructured":"Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019;1871:313\u201322.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9130_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366\u201379.","journal-title":"Cancer Biol Ther"},{"key":"9130_CR6","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/0008-5472.CAN-18-2864","volume":"79","author":"J Po\u017aniak","year":"2019","unstructured":"Po\u017aniak J, Nsengimana J, Laye JP, O\u2019Shea SJ, Diaz JMS, Droop AP, et al. Genetic and environmental determinants of immune response to cutaneous melanoma. Cancer Res. 2019;79:2684\u201396.","journal-title":"Cancer Res"},{"key":"9130_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-53","volume":"10","author":"G Madonna","year":"2012","unstructured":"Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-\u03baB as potential target in the treatment of melanoma. J Transl Med. 2012;10:53.","journal-title":"J Transl Med"},{"key":"9130_CR8","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1128\/MCB.21.24.8428-8436.2001","volume":"21","author":"SD Westerheide","year":"2001","unstructured":"Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol. 2001;21:8428\u201336.","journal-title":"Mol Cell Biol"},{"key":"9130_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2006.03.041","volume":"125","author":"R Massoumi","year":"2006","unstructured":"Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, F\u00e4ssler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125:665\u201377.","journal-title":"Cell"},{"key":"9130_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1084\/jem.20082044","volume":"206","author":"R Massoumi","year":"2009","unstructured":"Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206:221\u201332.","journal-title":"J Exp Med"},{"key":"9130_CR11","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cells10082136","volume":"10","author":"C De Vellis","year":"2021","unstructured":"De Vellis C, Pietrobono S, Stecca B. The role of glycosylation in melanoma progression. Cells. 2021;10:2136.","journal-title":"Cells"},{"key":"9130_CR12","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/cancers17122020","volume":"17","author":"J Srivastava","year":"2025","unstructured":"Srivastava J, Premi S. Targeting S-nitrosylation to overcome therapeutic resistance in NRAS-driven melanoma. Cancers. 2025;17:2020.","journal-title":"Cancers"},{"key":"9130_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08262-z","volume":"16","author":"Y Nakano","year":"2025","unstructured":"Nakano Y, Bustos MA, Chong KK, Hayashi Y, Ciechanover A, Hoon DSB. Ubiquitin E3 ligase KPC1 governs mesenchymal metastatic melanoma reprogramming via proteasomal degradation of ZEB1. Cell Death Dis. 2025;16:897.","journal-title":"Cell Death Dis"},{"key":"9130_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08216-5","volume":"16","author":"F Yi","year":"2025","unstructured":"Yi F, Liu S, Ma Y, Li Y, Chen B, Yu B. TRIM63\/IRF-8 axis promotes tumor progression and immunosuppression of melanoma with BRAF mutation. Cell Death Dis. 2025;16:869.","journal-title":"Cell Death Dis"},{"key":"9130_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07411-8","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhu J, He R, Xu L, Chen Y, Yu H, et al. Deubiquitination enzyme USP35 negatively regulates MAVS signaling to inhibit anti-tumor immunity. Cell Death Dis. 2025;16:138.","journal-title":"Cell Death Dis"},{"key":"9130_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"9130_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","volume":"81","author":"D Komander","year":"2012","unstructured":"Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203\u201329.","journal-title":"Annu Rev Biochem"},{"key":"9130_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander D, Clague MJ, Urb\u00e9 S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10:550\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9130_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cac2.70044","volume":"45","author":"S Zhu","year":"2025","unstructured":"Zhu S, Zhang X, Liu W, Zhou Z, Xiong S, Li J, et al. Ubiquitination in cancer: mechanisms and therapeutic opportunities. Cancer Commun. 2025;45:1128\u201361.","journal-title":"Cancer Commun"},{"key":"9130_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06419-w","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Yang C, Xie L, Shi F, Tang M, Luo X, et al. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma. Cell Death Dis. 2024;15:95.","journal-title":"Cell Death Dis"},{"key":"9130_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06464-5","volume":"15","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wu S, Fan J, Meng Z, Gao G, Liu T, et al. CYLD regulates cell ferroptosis through Hippo\/YAP signaling in prostate cancer progression. Cell Death Dis. 2024;15:79.","journal-title":"Cell Death Dis"},{"key":"9130_CR22","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.tibs.2019.08.004","volume":"44","author":"F Bernassola","year":"2019","unstructured":"Bernassola F, Chillemi G, Melino G. HECT-Type E3 ubiquitin ligases in cancer. Trends Biochem Sci. 2019;44:1057\u201375.","journal-title":"Trends Biochem Sci"},{"key":"9130_CR23","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.7150\/ijbs.69411","volume":"18","author":"S Han","year":"2022","unstructured":"Han S, Wang R, Zhang Y, Li X, Gan Y, Gao F, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022;18:2292\u2013303.","journal-title":"Int J Biol Sci"},{"key":"9130_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188736","volume":"1877","author":"HB Park","year":"2022","unstructured":"Park HB, Baek KH. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochim Biophys Acta Rev Cancer. 2022;1877:188736.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9130_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.cell.2026.01.029","volume":"189","author":"NK Chua","year":"2026","unstructured":"Chua NK, Gonz\u00e1lez-Robles TJ, Reddington CJ, Dudley-Fraser J, Birkinshaw RW, Han J, et al. The E3-ome gene-centric compendium reveals the human E3 ligase landscape. Cell. 2026;189:2167\u201388.e2127.","journal-title":"Cell"},{"key":"9130_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2013.05.046","volume":"154","author":"TE Mevissen","year":"2013","unstructured":"Mevissen TE, Hospenthal MK, Geurink PP, Elliott PR, Akutsu M, Arnaudo N, et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell. 2013;154:169\u201384.","journal-title":"Cell"},{"key":"9130_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","volume":"22","author":"H Mao","year":"2025","unstructured":"Mao H, Zhao X, Sun SC. NF-\u03baB in inflammation and cancer. Cell Mol Immunol. 2025;22:811\u201339.","journal-title":"Cell Mol Immunol"},{"key":"9130_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/15384047.2021.1978785","volume":"22","author":"OM El Yaagoubi","year":"2021","unstructured":"El Yaagoubi OM, Oularbi L, Bouyahya A, Samaki H, El Antri S, Aboudkhil S. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-\u03baB signal transduction. Cancer Biol Ther. 2021;22:479\u201392.","journal-title":"Cancer Biol Ther"},{"key":"9130_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.molcel.2017.06.011","volume":"67","author":"VY Wang","year":"2017","unstructured":"Wang VY, Li Y, Kim D, Zhong X, Du Q, Ghassemian M, et al. Bcl3 phosphorylation by Akt, Erk2, and IKK is required for its transcriptional activity. Mol Cell. 2017;67:484\u20135.","journal-title":"Mol Cell"},{"key":"9130_CR30","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1128\/MCB.01600-09","volume":"30","author":"A Keutgens","year":"2010","unstructured":"Keutgens A, Shostak K, Close P, Zhang X, Hennuy B, Aussems M, et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol. 2010;30:4006\u201321.","journal-title":"Mol Cell Biol"},{"key":"9130_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molcel.2004.09.004","volume":"16","author":"P Viatour","year":"2004","unstructured":"Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004;16:35\u201345.","journal-title":"Mol Cell"},{"key":"9130_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nature01811","volume":"424","author":"TR Brummelkamp","year":"2003","unstructured":"Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003;424:797\u2013801.","journal-title":"Nature"},{"key":"9130_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nature01803","volume":"424","author":"E Trompouki","year":"2003","unstructured":"Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003;424:793\u20136.","journal-title":"Nature"},{"key":"9130_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nature01802","volume":"424","author":"A Kovalenko","year":"2003","unstructured":"Kovalenko A, Chable-Bessia C, Cantarella G, Isra\u00ebl A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003;424:801\u20135.","journal-title":"Nature"},{"key":"9130_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/cdd.2017.46","volume":"24","author":"M Lork","year":"2017","unstructured":"Lork M, Verhelst K, Beyaert R. CYLD, A20 and OTULIN deubiquitinases in NF-\u03baB signaling and cell death: so similar, yet so different. Cell Death Differ. 2017;24:1172\u201383.","journal-title":"Cell Death Differ"},{"key":"9130_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/cdd.2009.43","volume":"17","author":"SC Sun","year":"2010","unstructured":"Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010;17:25\u201334.","journal-title":"Cell Death Differ"},{"key":"9130_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00555-1","volume":"19","author":"J Wang","year":"2024","unstructured":"Wang J, Ye J, Liu R, Chen C, Wang W. TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability. Biol Direct. 2024;19:106.","journal-title":"Biol Direct"},{"key":"9130_CR38","doi-asserted-by":"publisher","first-page":"14135","DOI":"10.1074\/jbc.RA119.010119","volume":"294","author":"A Uematsu","year":"2019","unstructured":"Uematsu A, Kido K, Takahashi H, Takahashi C, Yanagihara Y, Saeki N, et al. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD. J Biol Chem. 2019;294:14135\u201348.","journal-title":"J Biol Chem"},{"key":"9130_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nm.4461","volume":"24","author":"YX Ji","year":"2018","unstructured":"Ji YX, Huang Z, Yang X, Wang X, Zhao LP, Wang PX, et al. The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. Nat Med. 2018;24:213\u201323.","journal-title":"Nat Med"},{"key":"9130_CR40","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.18632\/oncotarget.1971","volume":"5","author":"X Wu","year":"2014","unstructured":"Wu X, Fukushima H, North BJ, Nagaoka Y, Nagashima K, Deng F, et al. SCF\u03b2-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination. Oncotarget. 2014;5:4211\u201321.","journal-title":"Oncotarget"},{"key":"9130_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccr.2008.10.007","volume":"14","author":"J An","year":"2008","unstructured":"An J, Mo D, Liu H, Veena MS, Srivatsan ES, Massoumi R, et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell. 2008;14:394\u2013407.","journal-title":"Cancer Cell"},{"key":"9130_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08482-x","volume":"17","author":"Y Ren","year":"2026","unstructured":"Ren Y, Zhou F, Tan Z, Yang S, Zhang S, Zhang Y, et al. OTUD4 deubiquitination stabilizes EGFR and activates the PI3K\/AKT pathway to promote the invasiveness of triple-negative breast cancer. Cell Death Dis. 2026;17:245.","journal-title":"Cell Death Dis"},{"key":"9130_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72791-0","volume":"10","author":"PW Jaynes","year":"2020","unstructured":"Jaynes PW, Iyengar PV, Lui SKL, Tan TZ, Vasilevski N, Wright SCE, et al. OTUD4 enhances TGF\u03b2 signalling through regulation of the TGF\u03b2 receptor complex. Sci Rep. 2020;10:15725.","journal-title":"Sci Rep"},{"key":"9130_CR44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10495-024-01953-6","volume":"29","author":"Z Li","year":"2024","unstructured":"Li Z, Tian Y, Zong H, Wang X, Li D, Keranmu A, et al. Deubiquitinating enzyme OTUD4 stabilizes RBM47 to induce ATF3 transcription: a novel mechanism underlying the restrained malignant properties of ccRCC cells. Apoptosis. 2024;29:1051\u201369.","journal-title":"Apoptosis"},{"key":"9130_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.114011","volume":"147","author":"M Li","year":"2025","unstructured":"Li M, Tian Y, Si L, Fu H, Lai T, Guo R. OTUD4-mediated inhibition of YAP1 signaling pathway in ovarian cancer: implications for macrophage polarization and recruitment. Int Immunopharmacol. 2025;147:114011.","journal-title":"Int Immunopharmacol"},{"key":"9130_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0816-z","volume":"19","author":"Z Wu","year":"2019","unstructured":"Wu Z, Qiu M, Guo Y, Zhao J, Liu Z, Wang H, et al. OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair. Cancer Cell Int. 2019;19:99.","journal-title":"Cancer Cell Int"},{"key":"9130_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-022-02533-9","volume":"41","author":"M Di","year":"2022","unstructured":"Di M, Miao J, Pan Q, Wu Z, Chen B, Wang M, et al. OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis. J Exp Clin Cancer Res. 2022;41:328.","journal-title":"J Exp Clin Cancer Res"},{"key":"9130_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06569-x","volume":"15","author":"M Ci","year":"2024","unstructured":"Ci M, Zhao G, Li C, Liu R, Hu X, Pan J, et al. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway. Cell Death Dis. 2024;15:179.","journal-title":"Cell Death Dis"},{"key":"9130_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06131-1","volume":"14","author":"L Luo","year":"2023","unstructured":"Luo L, Li T, Zeng Z, Li H, He X, Chen Y. CSE reduces OTUD4 triggering lung epithelial cell apoptosis via PAI-1 degradation. Cell Death Dis. 2023;14:614.","journal-title":"Cell Death Dis"},{"key":"9130_CR50","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.15252\/embj.201490497","volume":"34","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Majid MC, Soll JM, Brickner JR, Dango S, Mosammaparast N. Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase. Embo J. 2015;34:1687\u2013703.","journal-title":"Embo J"},{"key":"9130_CR51","doi-asserted-by":"publisher","first-page":"e1011943","DOI":"10.1371\/journal.ppat.1011943","volume":"20","author":"S Wang","year":"2024","unstructured":"Wang S, Tian X, Zhou Y, Xie J, Gao M, Zhong Y, et al. Non-canonical regulation of the reactivation of an oncogenic herpesvirus by the OTUD4-USP7 deubiquitinases. PLoS Pathog. 2024;20:e1011943.","journal-title":"PLoS Pathog"},{"key":"9130_CR52","doi-asserted-by":"publisher","first-page":"e1013052","DOI":"10.1371\/journal.ppat.1013052","volume":"21","author":"S Wang","year":"2025","unstructured":"Wang S, Tian X, Zhong Y, Xie X, Gao M, Zhang C, et al. Disrupting the OTUD4-USP7 deubiquitinase complex to suppress herpesvirus replication: a novel antiviral strategy. PLoS Pathog. 2025;21:e1013052.","journal-title":"PLoS Pathog"},{"key":"9130_CR53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.molcel.2018.01.009","volume":"69","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Mudge MC, Soll JM, Rodrigues RB, Byrum AK, Schwarzkopf EA, et al. OTUD4 Is a Phospho-activated K63 deubiquitinase that regulates MyD88-dependent signaling. Mol Cell. 2018;69:505\u2013516.e505.","journal-title":"Mol Cell"},{"key":"9130_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110784","volume":"301","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wang X, Wu L, Min L, Sheng Y, Sun Z, et al. The deubiquitinase OTUD4 suppresses TAK1 kinase-dependent NF-\u03baB signaling and inflammation. J Biol Chem. 2025;301:110784.","journal-title":"J Biol Chem"},{"key":"9130_CR55","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.molcel.2016.08.001","volume":"63","author":"PR Elliott","year":"2016","unstructured":"Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, et al. SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling. Mol Cell. 2016;63:990\u20131005.","journal-title":"Mol Cell"},{"key":"9130_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07969-3","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Feng X, Liu Z, Deng Y, Sun Z, Chen B, et al. USP7 promotes temozolomide resistance by stabilizing MGMT in glioblastoma. Cell Death Dis. 2025;16:631.","journal-title":"Cell Death Dis"},{"key":"9130_CR57","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1541-7786.MCR-07-0344","volume":"6","author":"L Xu","year":"2008","unstructured":"Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 2008;6:760\u20139.","journal-title":"Mol Cancer Res"},{"key":"9130_CR58","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","volume":"11","author":"D Talantov","year":"2005","unstructured":"Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234\u201342.","journal-title":"Clin Cancer Res"},{"key":"9130_CR59","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D, O\u2019Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106:20429\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9130_CR60","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22:2622.","journal-title":"Int J Mol Sci"},{"key":"9130_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"9130_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41556-021-00732-8","volume":"23","author":"G Zhu","year":"2021","unstructured":"Zhu G, Herlyn M, Yang X. TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nat Cell Biol. 2021;23:978\u201391.","journal-title":"Nat Cell Biol"},{"key":"9130_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0169-4","volume":"8","author":"MM de Jel","year":"2019","unstructured":"de Jel MM, Schott M, Lamm S, Neuhuber W, Kuphal S, Bosserhoff AK. Loss of CYLD accelerates melanoma development and progression in the Tg(Grm1) melanoma mouse model. Oncogenesis. 2019;8:56.","journal-title":"Oncogenesis"},{"key":"9130_CR64","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1084\/jem.20070318","volume":"204","author":"N H\u00f6velmeyer","year":"2007","unstructured":"H\u00f6velmeyer N, Wunderlich FT, Massoumi R, Jakobsen CG, Song J, W\u00f6rns MA, et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med. 2007;204:2615\u201327.","journal-title":"J Exp Med"},{"key":"9130_CR65","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.7150\/ijbs.58514","volume":"17","author":"J Wang","year":"2021","unstructured":"Wang J, Tan L, Jia B, Yu X, Yao R, N OU, et al. Downregulation of m(6)A reader YTHDC2 promotes the proliferation and migration of malignant lung cells via CYLD\/NF-\u03baB pathway. Int J Biol Sci. 2021;17:2633\u201351.","journal-title":"Int J Biol Sci"},{"key":"9130_CR66","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/emboj.2011.85","volume":"30","author":"J Staal","year":"2011","unstructured":"Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. Embo J. 2011;30:1742\u201352.","journal-title":"Embo J"},{"key":"9130_CR67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.celrep.2016.08.080","volume":"17","author":"LR Klei","year":"2016","unstructured":"Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, et al. MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. Cell Rep. 2016;17:221\u201332.","journal-title":"Cell Rep"},{"key":"9130_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01922-8","volume":"23","author":"G Seaton","year":"2024","unstructured":"Seaton G, Smith H, Brancale A, Westwell AD, Clarkson R. Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Mol Cancer. 2024;23:7.","journal-title":"Mol Cancer"},{"key":"9130_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-152","volume":"10","author":"V Maldonado","year":"2011","unstructured":"Maldonado V, Melendez-Zajgla J. Role of Bcl-3 in solid tumors. Mol Cancer. 2011;10:152.","journal-title":"Mol Cancer"},{"key":"9130_CR70","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","volume":"20","author":"MJ Clague","year":"2019","unstructured":"Clague MJ, Urb\u00e9 S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol. 2019;20:338\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9130_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/jid.2012.253","volume":"133","author":"H Ke","year":"2013","unstructured":"Ke H, Augustine CK, Gandham VD, Jin JY, Tyler DS, Akiyama SK, et al. CYLD inhibits melanoma growth and progression through suppression of the JNK\/AP-1 and \u03b21-integrin signaling pathways. J Invest Dermatol. 2013;133:221\u20139.","journal-title":"J Invest Dermatol"},{"key":"9130_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/emboj.2009.317","volume":"29","author":"SA Wickstr\u00f6m","year":"2010","unstructured":"Wickstr\u00f6m SA, Masoumi KC, Khochbin S, F\u00e4ssler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. Embo J. 2010;29:131\u201344.","journal-title":"Embo J"},{"key":"9130_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4898","volume":"5","author":"SI Gringhuis","year":"2014","unstructured":"Gringhuis SI, Kaptein TM, Wevers BA, Mesman AW, Geijtenbeek TB. Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKK\u03b5- and CYLD-dependent Bcl3 activation. Nat Commun. 2014;5:3898.","journal-title":"Nat Commun"},{"key":"9130_CR74","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/bph.17467","volume":"182","author":"K Saamarthy","year":"2025","unstructured":"Saamarthy K, Daams R, Sime W, Persson C, Chygorin E, Ahlqvist K, et al. An optimised Bcl-3 inhibitor for melanoma treatment. Br J Pharmacol. 2025;182:2426\u201346.","journal-title":"Br J Pharmacol"},{"key":"9130_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11663-y","volume":"24","author":"K Saamarthy","year":"2024","unstructured":"Saamarthy K, Ahlqvist K, Daams R, Balagunaseelan N, Rinaldo-Matthis A, Kazi JU, et al. Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells. BMC Cancer. 2024;24:103.","journal-title":"BMC Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09130-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:17:50Z","timestamp":1792711070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09130-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9130"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09130-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All experimental procedures for the animal study were approved by the Biomedical Research Ethics Committee of Hunan Normal University (Approval No. Lun Shen Ke 2024-823) and were conducted in accordance with the legal mandates and national guidelines for the care and maintenance of laboratory animals.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"904"}}